I-<it>kappa</it>-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma
<p>Abstract</p> <p>Background</p> <p>IKK-2 is an important regulator of the nuclear factor-κB (NF-κB) which has been implicated in survival, proliferation and apoptosis resistance of lymphoma cells. In this study, we investigated whether inhibition of IKK-2 impacts cell...
Main Authors: | Al-Katib Ayad, Arnold Alan A, Aboukameel Amro, Sosin Angela, Smith Peter, Mohamed Anwar N, Beck Frances W, Mohammad Ramzi M |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | Molecular Cancer |
Online Access: | http://www.molecular-cancer.com/content/9/1/228 |
Similar Items
-
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
by: Yang Dajun, et al.
Published: (2009-12-01) -
Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X<sub>L </sub>and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
by: Al-Katib Ayad, et al.
Published: (2008-02-01) -
Peripheral Neuropathy in Non-Hodgkin’s Lymphoma Patients Receiving Vincristine with and Without Aprepitant/Fosaprepitant
by: Edwards, Jessi K., et al.
Published: (2020) -
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model
by: Irfana Muqbil, et al.
Published: (2019-08-01) -
SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
by: Aboukameel Amro, et al.
Published: (2009-02-01)